Global nanomedicine market to be worth $258 billion by 2025, says report

27 May 2021

The worldwide nanomedicine market, which was worth $141.34 billion in 2020, will rise to $258.11 billion by 2025.

That is according to a report by marketdataforecast.com that has been highlighted by The World Nano Foundation and Nano Magazine as evidence of the investments flooding into nanomedicine healthcare companies.

The report also highlights a huge upsurge of investment support from governments and funds to develop nano therapies for vaccines, diagnostic imaging, regenerative medicine, and drug delivery following the impact of COVID-19.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK